XML 44 R33.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table represents Evolent’s revenue disaggregated by line of business and product type (in thousands):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2025202420252024
Medicaid$227,535 $214,627 $608,677 $646,819 
Medicare128,714 238,527 353,074 794,160 
Commercial and other123,284 168,246 445,759 467,220 
Total$479,533 $621,400 $1,407,510 $1,908,199 
Performance Suite$286,935 $435,100 $857,873 $1,344,920 
Specialty Technology and Services Suite93,263 85,474 257,485 255,992 
Administrative Services57,811 59,396 170,882 178,735 
Cases41,524 41,430 121,270 128,552 
Total$479,533 $621,400 $1,407,510 $1,908,199 
Schedule of Contract with Customer, Asset and Liability
The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September 30, 2025 and December 31, 2024 (in thousands):
September 30, 2025December 31, 2024
Short-term receivables (1)
$406,061 $413,346 
Short-term deferred revenue1,871 2,507 
Long-term deferred revenue220 — 
————————
(1)Excludes pharmacy rebate receivable and pharmacy claims receivable.

Changes in deferred revenue for the nine months ended September 30, 2025 are as follows (in thousands):
Deferred revenue
Balance as of beginning-of-period$2,507 
Reclassification to revenue, as a result of performance obligations satisfied(1,671)
Cash received in advance of satisfaction of performance obligations1,255 
Balance as of end of period$2,091